APPLICATION OF VIP/NTM-REACTIVE NATURAL ANTIBODIES IN THERAPY OF HIV DISEASE

REFERENCES

• K., Karpas, F., Hill, M., Youle, V., Cullen, J., Gray, N., Byron, F., Hayhoe, M., Tenant-Flowers, L., Howard, D., Gilgen, K. J., Oates, D., Hawkins, B., Gazzard. Effects of passive immunization in patients with the acquired immunodeficiency syndromerelated complex and acquired immunodeficency syndrome. Proc. Natl. Acad. Sci. USA. 85: 9234–9238, 1988, [CSA]
   PubMed Web of Science ®Google Scholar
• K., Karpas, I. K., Hewlett, F., Hill, J., Gray, N., Byron, D., Gilgen, V., Bally, J. K., Oates, B., Gazzard, J. E., Epstein. Polimerase chain reaction evidence for HIV-1 Neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc. Natl. Acad. Sci. USA. 87: 7613–7617, 1990, [CSA]
   PubMed Web of Science ®Google Scholar
• A. M., Prince, H., Reesnik, D., Pascual, B., Horowitz, I., Hewlett, K., Murthy, K. E., Cobb, J. W., Eichberg. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Human Retrovir.. 7: 971–973, 1991, [CSA]
   PubMed Web of Science ®Google Scholar
• L. M., Cummnis, K. J., Weinhold, T. J., Matthews, A. J., Langlois, C. F., Perno, R. M., Condie, J. P., Allain. Preparation and characterization of an intravenous solution of Ig from human immunodeficency virus-serpositive donors. Blood. 77: 1111–1117, 1991
   Google Scholar
• J. M., Jacobson, N., Colman, N. A., Ostrow, R. W., Simson, D., Tomesch, L., Marlin, M., Rao, J. L., Mills, J., Clemens, A. M., Prince. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J. Infect. Dis. 168: 298–305, 1993
   PubMed Web of Science ®Google Scholar
• J., Levy, T., Youvan, M. L., Lee. and. Passive Hyperimmune Therapy Study Group, Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter double-blind controlled trial. Blood. 84: 2130–2135, 1994, [CSA]
   Google Scholar
• K., Osther, A., Wiik, F., Black, P., Skinhoj, G., Kellermann, K. E., Ugen, W., Williams, D. B., Weiner. PASSHIV-1 treatment of patients with HIV-1 infection: A preliminary report of a phase-1 trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS. 6: 1457–1465, 1993
   Google Scholar
• S., Jiang, K., Lin, A. E., Neurath. Enhancement of human immunodeficency virus type 1 (HIV-1) infection by antisera to peptide from the envelope glycoprotein gp120/41. J. Exp. Med.. 174: 1557–1563, 1991, [CROSSREF]
   PubMedGoogle Scholar
• S., Jiang, A. R., Neurath. Potential risk of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loop of HIV-1 isolates. AIDS. 6: 331–332, 1992
   Google Scholar
• G., Faust. Enhancing antibodies in HIV infection. Parasitology. 115, Suppl. S127–S215, 1997, [CROSSREF]
   Google Scholar
• L. A., Cavacini, A., Wisnewski, J. E., Peterson, D., Montefiori, C., Emes, M., Duval, G., Kingsbury, A., Wang, D., Scadden, M. R., Posner. A human anti-HIV autoantibodies enhances EBV transformation and HIV infection. Clin. Immunol.. 93: 263–273, 1999, [CROSSREF]
   Google Scholar
• V., Veljkovic, R., Metlas. HIV and idiotypic T-cell regulation: Another view. Immunol. Today. 15: 38, 1992
   Google Scholar
• R., Metlas, V., Veljkovic. Does HIV-1 gp120 manipulate humane immune network. Vaccine. 13: 355–359, 1995, [CSA], [CROSSREF]
   Google Scholar
• R., Metlas, D., Trajkovic, T., Srdic, V., Veljkovic, A., Colombatti. Human immunodeficency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. AIDS Res. Human Retrovir.. 15: 671–677, 1999, [CSA], [CROSSREF]
   Google Scholar
• R., Metlas, D., Trajkovic, T., Srdic, V., Veljkovic, A., Colombatti. Anti-V3 and anti-IgG antibodies of healthy individuals share complementary structures. J. Acquir. Immun. Defic. Synd.. 21: 266–270, 1991
   Google Scholar
• V., Veljkovic, R., Metlas, V., Jevtovic, W. W., Stringer. The role of passive immunization in HIV patients, A case report, Chest.. 120: 662–666, 2001
   Google Scholar
• S., Paul, S. I., Said. Human autoantibody to vasoactive intestinal peptide: Increased incidence in muscular exercise. Life Sci.. 43: 1079–1084, 1988, [CROSSREF]
   Google Scholar
• H., Kohler, P. L., Nara, S., Miller. Deceptive imprinting in the immune response to HIV-1 infection. Immunol. Today. 15: 475–478, 1994, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• D. D., Ho, C. J., Caplan, E. I., Rackauskas, E. M., Gurney. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Nature. 239: 1021–1024, 1988
   Google Scholar
• V., Veljkovic, R., Metlas. Identification of nanopeptide from HTLV-III, ARV-2 and LAV envelope gp120 determining binding of T4 cell surface protein. Cancer Biochem. Biophys.. 10: 191–206, 1988
   Google Scholar
• R. S., Pollard, W., Meier, P., Chow, J. J., Rosa, D. C., Wiley. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 definded by proteolytic digestion. Proc. Natl. Acad. Sci.. 88: 1320–1324, 1991, [CSA]
   Google Scholar
• M., Stevenson, S., Haggerty, C., Lamonica, A. M., Mann, C., Meier, A., Wasiak. Cloning and characterization of human immunodeficiency virus type I variants diminished in the ability to induce syncytium-independent cytolysis. J. Virol.. 64: 3792–3803, 1990, [CSA]
   Google Scholar
• L., Stamatatos, C., Cheng-Mayer. Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-formation ability. J. Virol.. 67: 5635–5639, 1993, [CSA]
   Google Scholar
• B. A., Watkins, M., Reitz, C. A., Wilson, K., Aldrich, A. E., Davis, M., Robert-Guroff. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: Evidence for multiple pathways. J. Virol.. 67: 7493–7500, 1993, [CSA]
   PubMed Web of Science ®Google Scholar
• I., Lemasson, V., Housset, B., Calas, C., Devaux. Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: Implications for the structure of Env. AIDS Res. Human. Retrovir.. 11: 1177–1186, 1995, [CSA]
   Google Scholar
• S., Paul, D. J., Volled, C. M., Beach, D. R., Johnson, M. J., Poweli, R. J., Massey. Catalytic hydrolysis of vasoactive intestinal peptide by human antibody. Science. 244: 1158–1162, 1989
   PubMed Web of Science ®Google Scholar
• S., Paul, R. S., Kalaga, G., Gololobov, D., Brenneman. D. Natural catalytic immunity is not restricted to autoantigenic substrates. Appl. Biochem. Biotechn.. 83: 71–82, 2000, [CSA], [CROSSREF]
   Google Scholar
• D. R., Branch, J. L. E., Valenta, S., Yousefi, D., Sakac, R., Singla, M. S., Bali, M. Xue, Zong. VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively Facilitates productive HIV-1 infection. AIDS. 16: 309–314, 2002, [CROSSREF]
   Google Scholar
• L. S., Redwine, C. B., Pert, D. J., Rone, R., Nixon, M., Vance, B., Sandler, M. D., Lumpkin, D. J., Dieter, M. R., Ruff. Peptide T blocks gp120/CCR5 chemokine receptor-mediated chemotaxis. Clinical Immunol.. 93: 124, 1999, [CROSSREF]
   PubMedGoogle Scholar
• E. R., Stiehm, C. V., Fletcher, P. E., Mofenson, M., Kang, T., Fenton, C. V., Sapan, W. A., Meyer III, M. K., Shearer, E., Hawkins, M. G., Fowler, P., Bouquin, L., Purdue, E. M., Sloand, G. J., Nemo, D., Wara, Y. J., Bryson, S. E., Starr, A., Petru, S., Burchett. for the. Pediatric AIDS Trials Group Protocol 273 Study Group. Use of human immunodeficiency virus (HIV) Human hyperimmune immunoglobulin in HIV type 1 infected children (Pediatric AIDS Clinical Trials Group Protocol 273). J. Infect. Dis.. 181: 548, 2000, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. A., McKeating, J., Gow, J., Goudsmit. et al.. Characterization of HIV-1 neutralization escape mutants. AIDS. 3: 777, 1989
   Google Scholar
• V., Veljkovic, R., Metlas, H., Kohler. et al.. AIDS epidemic at the beginning of third millennium: Time for a new AIDS vaccine strategy. Vaccine. 19: 1855–1862, 2001, [CSA], [CROSSREF]
   Google Scholar
• V., Hurez, S. V., Kaveri, A., Mouhoub, G., Dietrich, J. C., Mani, D., Klatzmann, M. D., Kazatchkine. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (Intravenous immunoglobulin, IVIg). Ther. Immunol.. 1: 269, 1994, [CSA]
   PubMedGoogle Scholar
• H., Bouhlal, H., Hocini, C., Quillent-Gregoire, V., Donkova, S., Rose, A., Amara, R., Longhi, N., Haeffner-Cavaillon, A., Beretta, S. V., Kaveri, M. D., Kazatchkine. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J. Immunol.. 166: 7606, 2001
   Google Scholar
• A. R., Neurath, N., Strick, P., Taylor, P., Rubinstein, C. E., Stevens. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistence to disease development. AIDS Res. Human Retrovir.. 6: 1183–1192, 1990, [CSA]
   Google Scholar
• V., Veljkovic, R., Metlas, D., Vojvodic, Lj., Cavor, A., Dujic, S., Zakhariev, C., Guarnaccia, S., Pongor. Natural autoantibodies crossreact with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120. Biochem. Biophys. Res. Commun.. 196: 1019–1024, 1993, [CROSSREF]
   Google Scholar